UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 18, 2006
HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
Maryland
(State or other jurisdiction
of incorporation)
|
|
814-00702
(Commission File Number)
|
|
74-3113410
(I.R.S. Employer Identification No.) |
525 University Avenue
Suite 700
Palo Alto, CA 94301
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (650) 289-3060
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
From July 1, 2006 through September 29, 2006, we entered into binding agreements to
invest approximately $81.5 million in structured mezzanine debt in nine new portfolio companies and
one existing portfolio company and made a $250,000 equity investment in one existing portfolio
company.
During this same period, we funded the following debt investments totalling $67.2 million
in nine new portfolio companies and five existing portfolio companies and made two equity
investments, one in a new portfolio company and one in an existing portfolio company.
| |
|
|
|
|
|
|
|
|
| Company |
|
|
|
Principal Business |
|
Funded Investment |
Affinity Express, Inc.
|
|
Senior Debt
|
|
Consumer and Business Services
|
|
$ |
296,298 |
|
Agami Systems, Inc.
|
|
Senior Debt
|
|
Electronics and Computer
Hardware
|
|
|
7,000,000 |
|
Atrenta, Inc.
|
|
Equity
|
|
Software
|
|
|
250,000 |
|
Aveo Pharmaceuticals
|
|
Senior Debt
|
|
Biopharmaceuticals
|
|
|
7,500,000 |
|
BabyUniverse, Inc.
|
|
Senior Debt
|
|
Consumer and Business Products
|
|
|
5,000,000 |
|
BARRX Medical, Inc.
|
|
Equity
|
|
Medical Devices and Equipment
|
|
|
1,500,000 |
|
EpiCept Corporation
|
|
Senior Debt
|
|
Biopharmaceuticals
|
|
|
10,000,000 |
|
ForeScout Technologies, Inc.
|
|
Senior Debt
|
|
Software
|
|
|
1,000,000 |
|
Gynesonics, Inc.
|
|
Senior Debt
|
|
Medical Devices and Equipment
|
|
|
2,000,000 |
|
Hedgestreet, Inc.
|
|
Senior Debt
|
|
Consumer and Business Services
|
|
|
3,000,000 |
|
Intelliden, Inc.
|
|
Senior Debt
|
|
Software
|
|
|
3,000,000 |
|
iWatt, Inc.
|
|
Senior Debt
|
|
Semiconductors
|
|
|
2,000,000 |
|
Luminuous Devices, Inc.
|
|
Senior Debt
|
|
Electronics and Computer
Hardware
|
|
|
10,000,000 |
|
Novasys Medical, Inc.
|
|
Senior Debt
|
|
Medical Devices and Equipment
|
|
|
6,000,000 |
|
Oatsystems, Inc.
|
|
Senior Debt
|
|
Software
|
|
|
3,000,000 |
|
Portola Pharmaceuticals, Inc.
|
|
Senior Debt
|
|
Biopharmaceuticals
|
|
|
5,625,000 |
|
|
|
|
|
Total investments
|
|
$ |
67,171,298 |
|
In addition, at September 29, 2006, we had unfunded commitments totaling approximately
$95.7 million. These commitments will be subject to the same underwriting and ongoing portfolio
maintenance as are the financial instruments that we hold. Since these commitments may expire
without being drawn upon, the total commitment amount does not necessarily represent future cash
requirements. In addition, we had extended non-binding term sheets to six prospective new portfolio
companies representing approximately $58.5 million of structured mezzanine debt investments. These
investments are subject to finalization of our due diligence and approval process as well as
negotiation of definitive agreements with the prospective portfolio company and, as a result, may
not result in completed investments.
As of September 29, 2006, we had $91.0 million outstanding under our securitization
credit facility.
During September 2006, we sold the assets of Optovia Corporation for approximately $2.6
million. We will record a realized loss on this investment in the third quarter which is estimated
to be approximately $2.7 million, which includes approximately $380,000 of legal expenses and
incentive fees paid to a third party and members of Optovia’s management.